The evolution towards ambulatory and day-case management of febrile neutropenia.
Febrile neutropenia (FN) is only second to chemotherapy administration as a cause of hospital admission during treatment for cancer. As FN may signify serious or life-threatening infection, management protocols have focussed on trying to prevent adverse outcomes in these patients. However, it is now possible to identify a subset of patients with FN at low risk of life-threatening complications in whom duration of hospitalisation and intensity of therapy can be reduced safely. This review discusses how the management of FN has evolved to enable patients identified as low risk to be treated on specific low risk management strategies, with an emphasis on some of the practical considerations for the implementation of such strategies.
Chisholm
Julia C
JC
Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK. chishj@gosh.nhs.uk
Dommett
Rachel
R
D000553:Ambulatory Care / Q000379:methods*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D005334:Fever / Q000188:drug therapy*; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy*; D018579:Patient Selection; D018570:Risk Assessment / Q000379:methods
D000900:Anti-Bacterial Agents